Dr Rebecca Lim PhD is the Senior VP of Scientific Affairs at Prescient Therapeutics, a Melbourne-based oncology-focused biotechnology company. Since joining Prescient at the start of 2021, she has taken OmniCAR as a discovery asset through to rigorous preclinical testing and process development. Her 15 years of academic research experience in cell therapies and regenerative medicine has enabled her to tackle aggressive timelines with this world-first covalent modular CAR-T system that aims to address some of the toughest cancers. In 2019, she was recognised as NHMRC’s top Career Development Fellow (Industry). In 2020, 2021 and, she was recognised as the most highly cited Australian researcher in the areas of embryology and developmental biology. To date, she has been the scientific lead for 6 cell therapy clinical trials in Australia. She continues to hold an adjunct Associate Professor position at Monash University and Research Group Leader at the Hudson Institute of Medical Research.